Elanix Biotechnologies AG announced the treatment of the first patient in a Phase I/II clinical trial with TWB-103 in adults with skin graft donor site wounds (DSW). The study is being conducted in Taiwan and Japan with partner Transwell Biotech Co., Ltd. TWB-103 is a novel gel formulation developed by Transwell Biotech, using skin fibroblast progenitor cells provided by Elanix. The study will be conducted at the Tri-Service General Hospital in Taipei as well as the Tokyo Medical University Hospital and the Nippon Medical School Hospital in Tokyo. The aim is to compare safety and efficacy of TWB-103 with standard of care TegadermTM skin dressing to TegadermTM alone in 30 individuals. Primary objectives are safety and healing time from DSW creation to 100% re-epithelialization.